应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
01477 欧康维视生物-B
未开盘 11-18 16:08:08
5.260
+0.160
+3.14%
最高
5.280
最低
4.900
成交量
170.70万
今开
5.090
昨收
5.100
日振幅
7.45%
总市值
43.08亿
流通市值
43.08亿
总股本
8.19亿
成交额
872.62万
换手率
0.21%
流通股本
8.19亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
罗欣药业最新公告：控股子公司山东罗欣拟公开挂牌出售乐康制药100%股权
证券之星 · 11-18 20:40
罗欣药业最新公告：控股子公司山东罗欣拟公开挂牌出售乐康制药100%股权
巴克莱分析师：2025年制药行业前景更具挑战
美港电讯 · 11-18 19:42
巴克莱分析师：2025年制药行业前景更具挑战
盘活资产 罗欣药业(002793.SZ)控股子公司拟公开挂牌出售乐康制药100%股权
智通财经 · 11-18 19:13
盘活资产 罗欣药业(002793.SZ)控股子公司拟公开挂牌出售乐康制药100%股权
歌礼制药-B(01672)11月18日斥资83.11万港元回购50万股
智通财经 · 11-18 18:18
歌礼制药-B(01672)11月18日斥资83.11万港元回购50万股
欧康维视生物-B(01477)11月18日斥资26.79万港元回购5.25万股
智通财经 · 11-18 18:05
欧康维视生物-B(01477)11月18日斥资26.79万港元回购5.25万股
普洛药业最新公告：控股子公司康裕制药收到左氧氟沙星片《药品补充申请批准通知书》
证券之星 · 11-18 17:31
普洛药业最新公告：控股子公司康裕制药收到左氧氟沙星片《药品补充申请批准通知书》
歌礼制药-B11月18日获主力加仓23万元 环比增加2200.00%
市场透视 · 11-18 16:15
歌礼制药-B11月18日获主力加仓23万元 环比增加2200.00%
【券商聚焦】高盛：美国生物技术和制药行业面临政策变动
金吾财讯 · 11-18 10:44
【券商聚焦】高盛：美国生物技术和制药行业面临政策变动
特朗普提名疫苗怀疑论者为卫生部长“吓坏”市场，曾誓言清理FDA
第一财经 · 11-16 15:57
特朗普提名疫苗怀疑论者为卫生部长“吓坏”市场，曾誓言清理FDA
我国在研新药数量跃居全球第二 后续将推动医药工业转型升级
美港电讯 · 11-16 15:04
我国在研新药数量跃居全球第二 后续将推动医药工业转型升级
辉瑞制药日内跌幅扩大至5%
每日经济新闻 · 11-15
辉瑞制药日内跌幅扩大至5%
再生元制药下跌1.58%，报770.11美元/股
金融界 · 11-15
再生元制药下跌1.58%，报770.11美元/股
欧康维视生物-B(01477)11月15日斥资75.45万港元回购14.85万股
智通财经 · 11-15
欧康维视生物-B(01477)11月15日斥资75.45万港元回购14.85万股
歌礼制药-B(01672)11月15日斥资96.2万港元回购60万股
智通财经 · 11-15
歌礼制药-B(01672)11月15日斥资96.2万港元回购60万股
广济药业：子公司广化制药拟增资扩股引入投资者
美港电讯 · 11-15
广济药业：子公司广化制药拟增资扩股引入投资者
广济药业最新公告：全资子公司广化制药拟增资扩股引入战略投资者
证券之星 · 11-15
广济药业最新公告：全资子公司广化制药拟增资扩股引入战略投资者
广济药业(000952.SZ)子公司广化制药拟通过公开挂牌引入战略投资者
智通财经 · 11-15
广济药业(000952.SZ)子公司广化制药拟通过公开挂牌引入战略投资者
歌礼制药-B(01672)上涨6.62%，报1.61元/股
金融界 · 11-15
歌礼制药-B(01672)上涨6.62%，报1.61元/股
特朗普“重大宣布”惊动华尔街！一张图看美股大跌行情：制药类股沦为“灾区”
FX168 · 11-15
特朗普“重大宣布”惊动华尔街！一张图看美股大跌行情：制药类股沦为“灾区”
歌礼制药－Ｂ(01672)股价上升5.298%，现价港币$1.59
阿斯达克财经 · 11-15
歌礼制药－Ｂ(01672)股价上升5.298%，现价港币$1.59
加载更多
公司概况
公司名称：
欧康维视生物-B
所属市场：
SEHK
上市日期：
--
主营业务：
欧康维视生物是一家主要从事眼科疗法发现、开发及商业化业务的中国控股公司。其主要产品包括OT-401（YUTIQ）、OT-1001（ZERVIATE）、OT-502（DEXYCU）、OT-301（NCX 470）、OT-101和OT-202等。该公司在中国境内开展业务。
发行价格：
--
{"stockData":{"symbol":"01477","market":"HK","secType":"STK","nameCN":"欧康维视生物-B","latestPrice":5.26,"timestamp":1731917288014,"preClose":5.1,"halted":0,"volume":1707000,"delay":0,"floatShares":819000000,"shares":819000000,"eps":-0.6300983,"marketStatus":"未开盘","marketStatusCode":0,"change":0.16,"latestTime":"11-18 16:08:08","open":5.09,"high":5.28,"low":4.9,"amount":8726205,"amplitude":0.07451,"askPrice":5.27,"askSize":2000,"bidPrice":5.26,"bidSize":24000,"shortable":3,"etf":0,"ttmEps":-0.5301478136700112,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1731979800000},"adr":0,"listingDate":1594310400000,"adjPreClose":5.1,"openAndCloseTimeList":[[1731893400000,1731902400000],[1731906000000,1731916800000]],"volumeRatio":1.4741716832314948,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01477","defaultTab":"news","newsList":[{"id":"2484345624","title":"罗欣药业最新公告：控股子公司山东罗欣拟公开挂牌出售乐康制药100%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2484345624","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484345624?lang=zh_cn&edition=full","pubTime":"2024-11-18 20:40","pubTimestamp":1731933615,"startTime":"0","endTime":"0","summary":"罗欣药业公告，公司控股子公司山东罗欣拟通过临沂产权交易中心以公开挂牌方式出售其全资子公司乐康制药100%股权，挂牌价为1.9亿元。本次交易完成后，山东罗欣不再持有乐康制药股权，乐康制药将不再纳入公司合并报表范围。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111800030151.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0001","01477","08058","BK0201","BK1574","BK0132","002793","BK1191","BK0239"],"gpt_icon":0},{"id":"2484625898","title":"巴克莱分析师：2025年制药行业前景更具挑战","url":"https://stock-news.laohu8.com/highlight/detail?id=2484625898","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484625898?lang=zh_cn&edition=full","pubTime":"2024-11-18 19:42","pubTimestamp":1731930130,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU0109394709.USD","LU0320765992.SGD","LU1093756168.USD","LU2456880835.USD","BK4007","AZN","LU2236285917.USD","NVO","LU1093756325.SGD","BK4532","IE00BKVL7J92.USD","BK4568","BK1574","BK1191","01477","LU1829250122.USD","BK4585","LU0154236417.USD","BK4588","LU2417539215.USD","LU0889565916.HKD","LU2462157665.USD","IE00BZ1G4Q59.USD"],"gpt_icon":0},{"id":"2484628949","title":"盘活资产 罗欣药业(002793.SZ)控股子公司拟公开挂牌出售乐康制药100%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2484628949","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484628949?lang=zh_cn&edition=full","pubTime":"2024-11-18 19:13","pubTimestamp":1731928390,"startTime":"0","endTime":"0","summary":"智通财经APP讯，罗欣药业(002793.SZ)公告，公司控股子公司山东罗欣药业集团股份有限公司(简称“山东罗欣”)拟通过公开挂牌方式出售其全资子公司山东罗欣乐康制药有限公司(简称“乐康制药”)100%股权，确定挂牌价为1.9亿元。本次交易完成后，公司控股子公司山东罗欣不再持有乐康制药股权，乐康制药将不再纳入公司合并报表的范围。公告称，本次交易有利于公司盘活资产，优化公司资源配置，增强公司的盈利能力和抗风险能力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212440.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0001","BK0132","BK1574","BK0239","BK0201","BK1191","01477","002793","08058"],"gpt_icon":0},{"id":"2484864470","title":"歌礼制药-B(01672)11月18日斥资83.11万港元回购50万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484864470","media":"智通财经","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484864470?lang=zh_cn&edition=full","pubTime":"2024-11-18 18:18","pubTimestamp":1731925114,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)发布公告，于2024年11月18日该公司斥资83.11万港元回购50万股，回购价格为每股1.60-1.68港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212369.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","BK1161","BK1515","01672","BK1191","BK1574"],"gpt_icon":0},{"id":"2484641712","title":"欧康维视生物-B(01477)11月18日斥资26.79万港元回购5.25万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484641712","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484641712?lang=zh_cn&edition=full","pubTime":"2024-11-18 18:05","pubTimestamp":1731924320,"startTime":"0","endTime":"0","summary":"智通财经APP讯，欧康维视生物-B(01477)发布公告，于2024年11月18日，该公司斥资26.79万港元回购5.25万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212351.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","01477","BK1191"],"gpt_icon":0},{"id":"2484800649","title":"普洛药业最新公告：控股子公司康裕制药收到左氧氟沙星片《药品补充申请批准通知书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2484800649","media":"证券之星","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484800649?lang=zh_cn&edition=full","pubTime":"2024-11-18 17:31","pubTimestamp":1731922263,"startTime":"0","endTime":"0","summary":"普洛药业公告，公司控股子公司康裕制药收到药监局下发的左氧氟沙星片《药品补充申请批准通知书》，批准增加0.25g规格。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111800024056.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000739","BK0060","BK1574","BK1191","01477","BK0188"],"gpt_icon":0},{"id":"2484107026","title":"歌礼制药-B11月18日获主力加仓23万元 环比增加2200.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484107026","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484107026?lang=zh_cn&edition=full","pubTime":"2024-11-18 16:15","pubTimestamp":1731917746,"startTime":"0","endTime":"0","summary":"11月18日, 歌礼制药-B股价涨3.70%，报收1.68元，成交金额275万元，换手率0.17%，振幅8.64%，量比0.73。歌礼制药-B今日主力资金净流入23万元，上一交易日主力净流入1万元，今日环比增加2200.00%。该股近5个交易日下跌0.59%，主力资金累计净流出70万元；近20日主力资金累计净流入141万元，其中净流入天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118161622abcbd9f7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118161622abcbd9f7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01477","BK1515","01672","BK1161","BK1574","BK1191"],"gpt_icon":0},{"id":"2484766019","title":"【券商聚焦】高盛：美国生物技术和制药行业面临政策变动","url":"https://stock-news.laohu8.com/highlight/detail?id=2484766019","media":"金吾财讯","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484766019?lang=zh_cn&edition=full","pubTime":"2024-11-18 10:44","pubTimestamp":1731897864,"startTime":"0","endTime":"0","summary":"高盛对生物技术和制药行业的整体看法是，尽管RFK Jr.过去的一些言论可能增加了市场的不确定性，但他的政策变化如果得以实施，最终可能会简化当前流程，并为患者和生物制药行业带来好处。高盛的分析显示，尽管存在政策变动的不确定性，但生物技术和制药行业的长期前景仍然看好。高盛建议投资者关注那些在政策变动中可能受益的公司，同时保持对行业动态的密切关注。","market":"other","thumbnail":"https://static.szfiu.com/news/20210625/NGY0MmI5YjBmZmE4NTQ4NTQ2MWJlYzY2MzQ2MDk2NDUy.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/NGY0MmI5YjBmZmE4NTQ4NTQ2MWJlYzY2MzQ2MDk2NDUy.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"282080","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","IE0002270589.USD","LU0106831901.USD","LU2237443622.USD","IE00BSNM7G36.USD","BK4550","IE00B19Z3581.USD","LU1668664300.SGD","LU2237443895.HKD","BK1574","LU2237443465.HKD","IE00B19Z3B42.SGD","BK4504","LU1791807156.HKD","BK4127","BK4588","01477","IE0034235188.USD","BK1191","BK4516","LU2237443549.SGD","IE00BFXG1179.USD","LU2237443382.USD","BK4585","BK4552","IE0004091025.USD","LU2237443978.SGD","LU2237438978.USD","IE0004086264.USD"],"gpt_icon":0},{"id":"2483823591","title":"特朗普提名疫苗怀疑论者为卫生部长“吓坏”市场，曾誓言清理FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2483823591","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483823591?lang=zh_cn&edition=full","pubTime":"2024-11-16 15:57","pubTimestamp":1731743845,"startTime":"0","endTime":"0","summary":"自“疫苗怀疑论者”罗伯特·肯尼迪（Robert F. Kennedy Jr.，也称“小肯尼迪”）被美国当选总统特朗普提名为美国卫生与公众服务部（HHS）部长以来，美国生物医药市场接连两天经历剧烈震荡。 周五收盘，美股上市医药公司股价普跌，标普500制药指数下跌约2%，疫苗股跌幅居前。Moderna股价下跌超过7%，辉瑞股价下跌近5%，B...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/OOl1TNyzvTGQkM-u9jGL-KVHv6m_iRTYm-0RiDv_PdD2MAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OOl1TNyzvTGQkM-u9jGL-KVHv6m_iRTYm-0RiDv_PdD2MAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20241116A05NRB00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20241116A05NRB00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["BK1574","BK4009","01477","HHS","BK1191"],"gpt_icon":0},{"id":"2483624655","title":"我国在研新药数量跃居全球第二 后续将推动医药工业转型升级","url":"https://stock-news.laohu8.com/highlight/detail?id=2483624655","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483624655?lang=zh_cn&edition=full","pubTime":"2024-11-16 15:04","pubTimestamp":1731740676,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["600056","BK1515","159883","09997","BK1222","06978","09996","BK1161","BK0250","BK0185","BK0082","BK1583","BK0188","BK1191","BK0175","01477","BK0028","BK1574","09939","159992","BK0010","159938","BK1100"],"gpt_icon":0},{"id":"2483377725","title":"辉瑞制药日内跌幅扩大至5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483377725","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483377725?lang=zh_cn&edition=full","pubTime":"2024-11-15 22:45","pubTimestamp":1731681936,"startTime":"0","endTime":"0","summary":"辉瑞制药日内跌幅扩大至5%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202411153241326025.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411153241326025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0225284248.USD","LU0321505439.SGD","IE000M9KFDE8.USD","SG9999003800.SGD","LU0456855351.SGD","LU0170899867.USD","IE00B19Z3B42.SGD","BK4592","PFE","BK4568","01477","SG9999002224.SGD","LU1883839398.USD","BK4581","BK4533","LU1057294990.SGD","SG9999013999.USD","LU0058720904.USD","LU0289739699.SGD","BK4585","BK1574","LU0234572021.USD","LU0306807586.USD","SG9999001176.USD","LU1066053197.SGD","LU0321505868.SGD","IE00BLSP4452.SGD","SG9999002232.USD","LU0122379950.USD","LU0868494617.USD","IE00B19Z3581.USD","SG9999011175.SGD","IE00BLSP4239.USD","BK4550","BK4534","LU1023059063.AUD","LU0306806265.USD","SGXZ57979304.SGD","IE0002270589.USD","LU0985481810.HKD","LU1894683348.USD","LU1066051498.USD","IE00BBT3K403.USD","LU0225771236.USD","LU1894683264.USD","BK1191","SG9999001176.SGD","BK4007","BK4588"],"gpt_icon":0},{"id":"2483837230","title":"再生元制药下跌1.58%，报770.11美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483837230","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483837230?lang=zh_cn&edition=full","pubTime":"2024-11-15 22:34","pubTimestamp":1731681277,"startTime":"0","endTime":"0","summary":"11月15日，再生元制药(REGN)开盘下跌1.58%，截至22:34，报770.11美元/股，成交4097.88万美元。财务数据显示，截至2024年09月30日，再生元制药收入总额104.13亿美元，同比增长7.54%；归母净利润34.95亿美元，同比增长25.09%。大事提醒：11月14日，再生元制药获花旗首次给予评级Neutral，目标价895美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/11/15223445361706.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["01477","BK1191","BK1574"],"gpt_icon":0},{"id":"2483321261","title":"欧康维视生物-B(01477)11月15日斥资75.45万港元回购14.85万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483321261","media":"智通财经","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483321261?lang=zh_cn&edition=full","pubTime":"2024-11-15 19:46","pubTimestamp":1731671208,"startTime":"0","endTime":"0","summary":"智通财经APP讯，欧康维视生物-B(01477)发布公告，该公司于2024年11月15日斥资75.45万港元回购14.85万股股份，每股回购价格为5.03-5.19港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1211793.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1191","01477"],"gpt_icon":0},{"id":"2483332867","title":"歌礼制药-B(01672)11月15日斥资96.2万港元回购60万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483332867","media":"智通财经","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483332867?lang=zh_cn&edition=full","pubTime":"2024-11-15 18:27","pubTimestamp":1731666467,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)发布公告，于2024年11月15日该公司斥资96.2万港元回购60万股，回购价格为每股1.49-1.66港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1211688.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01672","BK1574","01477","BK1515","BK1161","BK1191"],"gpt_icon":0},{"id":"2483346086","title":"广济药业：子公司广化制药拟增资扩股引入投资者","url":"https://stock-news.laohu8.com/highlight/detail?id=2483346086","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483346086?lang=zh_cn&edition=full","pubTime":"2024-11-15 16:54","pubTimestamp":1731660876,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1191","BK0191","BK1574","000952","01477","BK0239"],"gpt_icon":0},{"id":"2483346704","title":"广济药业最新公告：全资子公司广化制药拟增资扩股引入战略投资者","url":"https://stock-news.laohu8.com/highlight/detail?id=2483346704","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483346704?lang=zh_cn&edition=full","pubTime":"2024-11-15 16:53","pubTimestamp":1731660839,"startTime":"0","endTime":"0","summary":"广济药业公告，全资子公司广化制药拟在上海联合产权交易所预挂牌，通过增资扩股方式引入战略投资者。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111500026794.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","01477","BK1574","000952","BK0191","BK0239"],"gpt_icon":0},{"id":"2483346584","title":"广济药业(000952.SZ)子公司广化制药拟通过公开挂牌引入战略投资者","url":"https://stock-news.laohu8.com/highlight/detail?id=2483346584","media":"智通财经","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483346584?lang=zh_cn&edition=full","pubTime":"2024-11-15 16:43","pubTimestamp":1731660221,"startTime":"0","endTime":"0","summary":"智通财经APP讯，广济药业(000952.SZ)发布公告，公司全资子公司湖北广化制药有限公司(以下简称“广化制药”)拟在上海联合产权交易所预挂牌，通过增资扩股方式引入战略投资者。公告称，公司为降低投资风险，顺利推进广化制药化学合成原料药基地项目建设，确保该项目可持续发展，通过上海联合产权交易所公开挂牌引入战略投资者，符合公司整体战略发展需要。本次增资扩股完成后，广化制药将不再纳入公司合并报表范围。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1211510.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0191","000952","BK0239","01477","BK1191","BK1574"],"gpt_icon":0},{"id":"2483627397","title":"歌礼制药-B(01672)上涨6.62%，报1.61元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483627397","media":"金融界","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483627397?lang=zh_cn&edition=full","pubTime":"2024-11-15 13:00","pubTimestamp":1731646809,"startTime":"0","endTime":"0","summary":"11月15日，歌礼制药-B(01672)盘中上涨6.62%，截至13:00，报1.61元/股，成交116.1万元。歌礼制药有限公司是一家创新研发驱动型生物科技公司，主要从事病毒性疾病、非酒精性脂肪性肝炎和肿瘤等三大医疗领域的新药研发、生产和商业化。该公司在浙江绍兴滨海新城拥有约17,000平方米的生产基地，设计年产能为1.3亿片，拥有多款在研药物并已取得药品生产许可证。截至2023年年报，歌礼制药-B营业总收入5659.6万元、净利润-1.45亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/15130045328754.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1191","01672","BK1574","BK1515","01477","BK1161"],"gpt_icon":0},{"id":"2483392831","title":"特朗普“重大宣布”惊动华尔街！一张图看美股大跌行情：制药类股沦为“灾区”","url":"https://stock-news.laohu8.com/highlight/detail?id=2483392831","media":"FX168","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483392831?lang=zh_cn&edition=full","pubTime":"2024-11-15 12:48","pubTimestamp":1731646126,"startTime":"0","endTime":"0","summary":"FX168财经报社 讯 美国当选总统特朗普本周陆续宣布“新内阁”提名人选，他选择小肯尼迪担任美国卫生部长，周四美股惊现暴跌行情，疫苗制造商股价应声下滑，原因是小肯尼迪是美国知名的反疫苗者。Watcher.Guru在推特帖文中写道：“特朗普任命小肯尼迪为卫生与公众服务部部长后，制药类股票下跌。”由于自疫情高峰以来需求减少，美国疫苗公司已经陷入困境。过去一年，辉瑞股价下跌11%，Moderna股价暴跌46%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"8b50228a679c44f870e44bbf889089f6","isJumpTheme":false,"source_url":"https://www.fx168news.com/article/特朗普-799029","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VIXY","TVIX","01477","VIXmain","BK1574","SVXY","BK1191","UVXY"],"gpt_icon":0},{"id":"2483692394","title":"歌礼制药－Ｂ(01672)股价上升5.298%，现价港币$1.59","url":"https://stock-news.laohu8.com/highlight/detail?id=2483692394","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483692394?lang=zh_cn&edition=full","pubTime":"2024-11-15 11:56","pubTimestamp":1731642960,"startTime":"0","endTime":"0","summary":"[上升股]歌礼制药－Ｂ(01672) 股价在上午11:56比前收市价上升5.298%，现股价为港币$1.59。至目前为止，今日最高价为$1.59，而最低价为$1.48。总成交量为52.9万股，总成交金额为港币$80.671万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180725133914771_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180725133914771_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2411151200/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01477","BK1161","BK1191","BK1574","01672","BK1515"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ocumension.com","stockEarnings":[{"period":"1week","weight":-0.0131},{"period":"1month","weight":-0.1883},{"period":"3month","weight":-0.1085},{"period":"6month","weight":-0.2321},{"period":"1year","weight":-0.2892},{"period":"ytd","weight":-0.2126}],"compareEarnings":[{"period":"1week","weight":-0.0416},{"period":"1month","weight":-0.059},{"period":"3month","weight":0.118},{"period":"6month","weight":0.0198},{"period":"1year","weight":0.1216},{"period":"ytd","weight":0.1484}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"欧康维视生物是一家主要从事眼科疗法发现、开发及商业化业务的中国控股公司。其主要产品包括OT-401（YUTIQ）、OT-1001（ZERVIATE）、OT-502（DEXYCU）、OT-301（NCX 470）、OT-101和OT-202等。该公司在中国境内开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.137321},{"month":2,"riseRate":0.25,"avgChangeRate":-0.072355},{"month":3,"riseRate":0.5,"avgChangeRate":0.043389},{"month":4,"riseRate":0.25,"avgChangeRate":0.004659},{"month":5,"riseRate":0.5,"avgChangeRate":0.068025},{"month":6,"riseRate":0.75,"avgChangeRate":0.066459},{"month":7,"riseRate":0.5,"avgChangeRate":-0.028018},{"month":8,"riseRate":0.4,"avgChangeRate":-0.050881},{"month":9,"riseRate":0.2,"avgChangeRate":-0.087999},{"month":10,"riseRate":0.2,"avgChangeRate":-0.144034},{"month":11,"riseRate":0.4,"avgChangeRate":0.011854},{"month":12,"riseRate":0.75,"avgChangeRate":0.144341}],"exchange":"SEHK","name":"欧康维视生物-B","nameEN":"OCUMENSION-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"欧康维视生物-B,01477,欧康维视生物-B股票,欧康维视生物-B股票老虎,欧康维视生物-B股票老虎国际,欧康维视生物-B行情,欧康维视生物-B股票行情,欧康维视生物-B股价,欧康维视生物-B股市,欧康维视生物-B股票价格,欧康维视生物-B股票交易,欧康维视生物-B股票购买,欧康维视生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}